Chronic inflammation is involved in the onset and development of many diseases, including obesity, atherosclerosis, type 2 diabetes, osteoarthritis, autoimmune and degenerative diseases, asthma, periodontitis, and cirrhosis. The inflammation process is mediated by chemokines, cytokines, and different inflammatory cells. Although the molecules and mechanisms that regulate this primary defense mechanism are not fully understood, recent findings offer a putative role of noncoding RNAs, especially microRNAs (miRNAs), in the progression and management of the inflammatory response. These noncoding RNAs are crucial for the stability and maintenance of gene expression patterns that characterize some cell types, tissues, and biologic responses. Several miRNAs, such as miR-126, miR-132, miR-146, miR-155, and miR-221, have emerged as important transcriptional regulators of some inflammation-related mediators. Additionally, little is known about the involvement of long noncoding RNAs, long intergenic noncoding RNAs, and circular RNAs in inflammation-mediated processes and the homeostatic imbalance associated with metabolic disorders. These noncoding RNAs are emerging as biomarkers with diagnosis value, in prognosis protocols, or in the personalized treatment of inflammation-related alterations. In this context, this review summarizes findings in the field, highlighting those noncoding RNAs that regulate inflammation, with emphasis on recognized mediators such as TNF-a, IL-1, IL-6, IL-18, intercellular adhesion molecule 1, VCAM-1, and plasminogen activator inhibitor 1. The down-regulation or antagonism of the noncoding RNAs and the administration of exogenous miRNAs could be, in the near future, a promising therapeutic strategy in the treatment of inflammation-related
INFLAMMATION IS A COMPLEX PROTECTIVE process that requires a cross-talk between different types of immune cells to remove or neutralize harmful stimuli (1) . In the classic view, the inflammatory process is induced by an invasion of foreign pathogens of biologic origin or by tissue damage. Neutrophils, dendritic cells, and macrophages express almost all types of TLRs participating in the transmission of a signal from the plasma membrane through a multistep cascade to responsive transcription factors. Members of the TLR family have emerged as the primary evolutionarily conserved sensors of pathogen-associated molecular patterns (1) . Binding of the TLRs to their respective ligands initiates a wide spectrum of responses, from phagocytosis to production of a variety of cytokines, which in turn shape and enhance the inflammatory and adaptive immune responses. Typical transcription factors that activate inflammatory mediators are NF-kB (2), activator protein 1 (3), signal transducer and activator of transcription (STAT) (4), CCAAT enhancer binding protein (C/EBP) (5) , and Ets-like gene 1 (6) . The interactions between transcription factors that compete for binding sites in the promoter regions of specific target genes are highly complex. Usually the multistep signaling leads to a prompt transcription of genes resulting in accumulation of specific mRNAs coding for TNF-a, IL-1, IL-6, IL-8, monocyte chemotactic protein 1 (MCP-1), and other cytokines involved in inflammation (7) .
Some cytokines may elicit a broad inflammatory response, while others act on specific cell types. The activation, proliferation, and recruitment phenomena of specific differentiated immune cells are involved in resolving the nonhomeostatic state [for a review, see Shi (8) ]. Thus, macrophages stimulate the inflammatory responses of Abbreviations: ADAM17, ADAM (A disintegrin and metalloproteinase) metallopeptidase domain 17; AKT/GSK, protein kinase B/glycogen synthase kinase; BMI, body mass index; C/EBP, CCAAT enhancer binding protein; circRNA, circular RNA; COX-2, cyclooxygenase 2; CRP, C-reactive protein; ICAM-1, intercellular adhesion molecule 1; IL-1R, (continued on next page) neutrophils, fibroblasts, and endothelial cells (2) . Other sentinel cells may present antigens to the T-helper cells, which play a central role in coordinating immune responses, such as clonal expansion of T cells and B cell responses (9) . Acute inflammation is an important part of the immune response, but chronic inappropriate inflammation can cause metabolic disorders (10) . For example, chronic lowgrade inflammation has been repeatedly associated with the onset and prevalence of metabolic syndrome (11, 12) . The International Diabetes Federation estimates that one quarter of the world's adult population has metabolic syndrome (13) . This phenomenon is defined by a combination of interconnected cardiometabolic alterations that include the presence of arterial hypertension, insulin resistance, dyslipidemia, cardiovascular disease, and abdominal obesity (11) . With the pathologic enlargement of the adipose tissue in obesity, the blood supply to adipocytes may be reduced, with subsequent hypoxia leading to a an elevated production of proinflammatory mediators [TNFa and IL-6, plasminogen activator inhibitor-1 (PAI-1), and C-reactive protein (CRP)] and increased infiltration of immune cells, particularly adipose tissue macrophages (14, 15) . These altered signals mediate multiple processes, including insulin sensitivity (16) , oxidative stress (17) , energy metabolism, blood coagulation, and inflammatory responses (12) . These pathologic conditions predispose to diabetes mellitus, hepatic steatosis, atherosclerosis, plaque rupture, and atherothrombosis (11) . However, to date, the available information is controversial and does not necessarily imply an unequivocal causal role. The data obtained by functional genomics techniques indicate that several hundreds of genes participate in the inflammatory response and that their coordinated expression is tightly regulated [reviewed in Jura and Koj (18) ]. Nevertheless, the involved pathways and the regulatory mechanisms are not completely understood.
In the last few years, there has been a growing interest in the role of microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) in the development of several inflammation-related diseases ( Table 1) . These noncoding RNAs have emerged as important transcriptional regulators in both physiologic and pathophysiological conditions (19) (20) (21) . In physiologic homeostasis, these nucleic acids may participate in cell differentiation, proliferation, apoptosis, hematopoiesis, limb morphogenesis, and important metabolic pathways, such as insulin secretion, triglyceride and cholesterol biosynthesis, and oxidative stress (20, 22, 23) . Given their fundamental biologic roles, it is not surprising that miRNAs expression is tightly controlled and that its dysregulation can lead to disease onset.
Advances in basic biology combined with recent wholegenome and transcriptome studies demonstrate that the control of protein expression levels is far more dynamic and complex than previously presumed (24) . Gene transcription is regulated at different levels, but only some of them have been elucidated. Although miRNAs constitute only 3% of the human genome, it is estimated that they regulate approximately 90% of genes (23, 25) . The mechanisms are not fully understood, but it is known that miRNAs are crucial for the stability and maintenance of the gene expression patterns that characterize cell types, tissues, and biologic processes and responses (23) . miRNAs may act directly on the target genes or indirectly, by first regulating transcription factors that in turn control gene expression. Generally miRNAs bind to the target sequence located in the 39 UTR of their target mRNA through at least 6 to 8 nt long complementary sequences. They cause gene silencing mainly through degradation of target mRNA or inhibition of protein translation [for reviews, see Rebane and Akdis (24), Djuranovic et al. (26) , and Magenta et al. (27) ]. On the other hand, the lncRNAs are non-protein-coding RNAs longer than 200 nt. It has been reported that alterations in the levels of lncRNAs affect gene expression and thereby cell homeostasis (28) . In addition, miRNAs and lncRNAs do not abolish the expression of their target genes but only reduce the amount of mRNA and/or protein (22) .
Recent advances with the omics technologies have produced progress in the understanding of the role of noncoding RNAs on gene expression and cell metabolism in several processes, including inflammation and oxidative stress (20, 22, 29) . Moreover, miRNAs might provide a link between immune signaling pathways and might also play a role in controlling the switch from a strong early proinflammatory response to the resolution phase of the inflammatory process [for reviews, see O'Neill et al. (30) and Olivieri et al. (31) ]. In vitro and in vivo studies have demonstrated the essential participation of some of these RNAs in the production and regulation of several proinflammatory cytokines (21, 24, 32) . Collectively, these findings indicate a participation of miRNAs and lncRNAs in the onset, progression, and maintenance of several pathologies. Additionally, noncoding RNAs could have a role as new biomarkers with diagnostic value in prognosis protocols or in the personalized treatment of diseases related to metabolism (33) (34) (35) . In this context, this review summarizes available findings in the field, highlighting those noncoding RNAs that regulate the expression of important inflammation mediators, such as TNF-a, IL-1, IL-6, IL-18, PAI-1, intercellular adhesion molecule 1 (ICAM-1), and VCAM-1.
MIRNAS AND REGULATION OF INFLAMMATION
The molecular networks that control the onset, peak magnitude, and resolution of inflammation must be properly tuned for optimal health maintenance (36) . Both innate and adaptive immune responses are highly controlled, and recent studies have shed light on the epigenetic regulation in this intricate defense system (18, 37) . This type of regulation is termed epigenetic because it causes heritable changes in gene expression, but they are (continued from previous page) IL-1 receptor; IRAK, IL-1 receptor-associated kinase; lincRNA, long intergenic noncoding RNA; lncRNA, long noncoding RNA; MCP-1, monocyte chemotactic protein 1; miRNA, micro-RNA; MyD88, myleloid differentiation primary response protein 88; NLR, NOD-like receptor family; PAI-1, plasminogen activator inhibitor 1; Ppargc1b, peroxisome proliferator-activated receptor g, coactivator 1b; SHIP1, SH2 domain containing inositol-5-phosphatase 1; SOCS1, suppressor of cytokine signaling 1; STAT, signal transducer and activator of transcription; THP-1, human monocytic cell line; THRIL, TNF-and HNRNPL-related immunoregulatory lincRNA not accompanied by changes in DNA sequence (38) . In this context, the participation of several miRNAs in the regulation of inflammatory processes has been reported (24, 29, 39, 40) .
Each miRNA can target hundreds of mRNAs within a given cell type, and a single mRNA is often the target of multiple miRNAs (41) . Mechanistically, miRNAs have been implicated as negative regulators of inflammatory processes at the posttranscriptional level (30) . Additionally, miRNAs can regulate the transcription of other miRNAs (39) . Among many other miRNAs researched in this field, miR-146, miR-155, and miR-223 are probably the most intensively studied. They have been identified as inflammatory response miRNAs that are up-regulated by NF-kB (21, 39, 42) . Several studies indicate that miR-146 and miR-155 together play a key role in regulating several critical pathways that orchestrate innate immune responses and chronic inflammatory processes that are conserved across many different human tissue systems. This may be a consequence of their related ribonucleotide sequence (43) (44) (45) . The participation of the most relevant miRNAs in the inflammatory process is summarized in Table 2 .
Numerous miRNAs seem to function mainly in the regulation of inflammatory pathways, especially NF-kB signaling (46) . When inflammation is initiated, rapid transcriptional up-regulation of several proinflammatory cytokines occurs (24) . Simultaneously, the expression of numerous miRNAs is initiated by the same transcription factors. These miRNAs either silence the expression of the positive signaling proteins or the inhibitors of the same pathway (23, 41) . On the other hand, numerous miRNAs are also down-regulated during the activation of immune cells. When anti-inflammatory miRNAs are expressed at lower levels or proinflammatory miRNAs are expressed at higher levels, the immune system is overactivated and vice versa (24) . Thus, the dysregulation of miRNA expression can lead to immune deficiency, autoimmunity, or chronic infection (25, 31, 47, 48) .
Several reports have examined the involvement of the miRNAs in low-intensity inflammation related to obesity and associated diseases [for reviews, see Hulsmans et al. (20) , Aranda et al. (22) , and Schroen and Heymans (49) ]. In addition, obesity is associated with increased levels of blood monocytes (50) , which are already activated in the circulation and are characterized by an increase in NF-kB activity, in the transcription of proinflammatory genes (e.g., TNF-a and IL-6), and in the production of reactive oxygen species, as described elsewhere (14) . Recent computational and experimental studies have shown that miRNAs appear to play regulatory roles in many biologic processes associated with obesity, including adipocyte differentiation and lipid metabolism (51) . In addition, many 
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The expression of these miRNAs is much higher in periodontitis gingivae than in healthy ones. Primary murine macrophages (44) miR-155 represses the expression of B cell lymphoma 6, a transcription B cell lymphoma of mice (206) (continued on next page) miRNAs are dysregulated in metabolic tissues from obese animals and humans, which potentially contributes to the pathogenesis of obesity-associated complications (20, 51) . For example, a cross-sectional validation study reported that 15 specific circulating miRNAs were significantly deregulated in prepubertal obesity, including a decrease of miR-221 and miR-28-3p and an increase of miR-486-5p, miR-486-3p, miR-142-3p, miR-130b, and miR-423-5p in plasma (52) . The circulating concentrations of these miRNAs were significantly associated with body mass index (BMI) and other measures of obesity, such as percentage fat mass, waist circumference, and regional fat distribution, and with laboratory parameters, including homeostasis model assessment of insulin resistance, high-molecular-weight 
Overexpression of miR-181b inhibits importin a3 expression and an enriched set of NF-kB-responsive genes, such as adhesion molecules VCAM-1 and E-selectin in vitro and in vivo.
HUVECs, THP-1 cells, male C57BL/6 mice, and human plasma (208) miR-187 TNF-a, IL-6 and IL-12 miR-187 negatively regulates cytokine production.
TLR4-stimulated monocytes (209) miR-221 ICAM-1 HIV-1 viral protein TAT modulates ICAM-1 expression via mir-221/-222.
HUVECs and HIV transgenic rats (129) miR-221 is up-regulated in obese subjects, associated with BMI in adipose tissue, and down-regulated during preadipocyte differentiation and adipocyte maturation.
Subcutaneous human preadipocytes and adipose tissue biopsy samples (130) miR-221 suppresses ICAM-1 translation and regulates IFN-g-induced ICAM-1 expression.
Human cholangiocytes (131) TNF-a miR-221 is down-regulated by TNF-a treatment.
Human preadipocytes (77) miR-222 ICAM-1 miR-222 reduces ICAM-1 expression and prevents the association of cytotoxic T lymphocyte cells to tumor cells.
Primary human glioblastoma multiforme tissue and human colorectal cancer cells (132) miR-223 PAI-1 miR-223 prevents accumulation of NLR family, pyrin domain containing 3 (NLRP3) protein and inhibits IL-1b production from the inflammasome.
Human primary monocytes (210) miR-30c miR-30c inhibits both PAI-1 mRNA and protein levels.
HUVEC/plasma samples from humans (151) miR-30c cosilences PAI-1 and activin receptor-like kinase 2 (ALK2) and up-regulates adipogenic key transcription factors, such as PPARg and C/EBP-a.
Human multipotent adipose-derived stem cells (152) miR-421 miR-421 inhibits both PAI-1 mRNA and protein levels. miR-421 plasma levels are increased in patients with high PAI-1 plasma levels.
HUVEC/plasma samples from humans (151) miR-449a/b Hypoxia and reactive oxygen species decrease miR-449a/b and increases PAI-1 expression.
Hypoxic fibroblasts
Let-7 IL-6 Let-7 decreases expression of IL-6. Transfection in bone marrow-derived mesenchymal stem cells (118) NONCODING RNAS AND CYTOKINESadiponectin, CRP, and circulating lipids in concordance with anthropometric associations (52) . Thus, the very early detection of an abnormal circulating miRNA profile may be a promising strategy to identify obese children who may experience metabolic abnormalities accompanied by inflammation. The main miRNAs involved in the obesity pathophysiology are summarized in Fig. 1 . miRNAs modulate not only fat mass size but also the metabolic consequences of obesity and adipose tissue metabolism (53) . A set of miRNAs (including miR-103, miR-107, and miR-143) are induced during adipogenesis (which may accelerate fat cell development) but are downregulated in the obese state (54) . In fact, there are many miRNAs involved in the regulation of adipogenesis, although it is not the main focus of this review. Adipocyte differentiation is not directly implicated in local inflammation, but chronic low-grade inflammation in the adipose tissue is usually associated with a reduction of the adipogenic capacity and an inability to increase adipose tissue mass by adipocyte hyperplasia. As a consequence, it leads to adipocyte hypertrophy and increased hypoxia, endoplasmic reticulum stress, adipocyte senescence, autophagy, apoptosis, necrosis, and death, which in turn aggravate lipotoxicity, macrophage infiltration, insulin resistance, and local and systemic inflammation (55) . On the other hand, mouse models with an adipose tissue-specific reduction in proinflammatory potential display a reduced adipogenic capacity, whereas an impaired local proinflammatory response in the adipocyte leads to increased ectopic lipid accumulation, glucose intolerance, and systemic inflammation (56) . These observations have important implications for understanding adipose tissue deregulation in obese mice and humans as well as the link between insulin and chronic inflammation and obesity (54) . In addition to altered adipocyte miRNA expression during obesity, there is an altered expression of miRNAs in the circulation (57) and in peripheral blood mononuclear cells (58) . Moreover, the basal expression of certain miRNAs in blood cells can differentiate between those who will respond and not respond (miR-935, miR-4772, miR-223, and miR-376b) to diet-induced weight loss (58) . Another important miRNA is miR-378. Mice genetically lacking miR-378 and miR-378*, while leaving the host gene peroxisome proliferator-activated receptor g, coactivator 1b (Ppargc1b), intact, are resistant to high-fat diet-induced obesity and exhibit enhanced mitochondrial fatty acid metabolism and elevated oxidative capacity of insulin target tissues (59) . In this context, the role of miRNAs in the regulation of the expression of some of the main molecules involved in the inflammatory processes will be discussed.
MIRNAS AND INFLAMMATORY CYTOKINES
Cytokines are a broad and loose category of small proteins (;5-20 kDa) that are important in cell signaling (9) . These mediators are released by cells and affect the behavior of other cells, and sometimes the releasing cell itself (60) . The cytokines play a central role in whole body homeostasis by influencing a variety of biologic and physiologic processes (61) . Some of them control food intake, energy balance, insulin action, lipid and glucose metabolism, angiogenesis and vascular remodeling, blood Figure 1 . Summary of some miRNAs involved in obesity pathophysiology and related inflammation. Obesity-associated inflammation is characterized by macrophage infiltration into adipose tissue, cytokine production, decrease of triglyceride storage, stimulation of lipolysis, and impairment of insulin signaling (185) . Adipose tissue hypoxia, increased hypertrophy, and adipocyte death are associated with chronic inflammation and insulin resistance in obesity. Both inflammation and hypoxia inhibit new adipocyte differentiation from preadipocytes (185) and lead to endoplasmic reticulum stress, adipocyte senescence, autophagy, and apoptosis, which in turn aggravate insulin resistance and local and systemic inflammation (55) . In obesity, changes in miRNA expression profiles may induce adipocyte dysfunction. miR-103, miR-107, miR-143, and miR-185 are up-regulated in lean subjects and down-regulated in obese subjects, whereas miR-27a/b and miR-100 are down-regulated in lean subjects and up-regulated in obese subjects (54, 130) . Regarding adipocyte differentiation, in human stem cells derived from subcutaneous adipose tissue, miR-21 antagonizes TGF-b signaling and increases adipogenesis (186) . Mesenchymal stem cells overexpressing miR-221 and miR-222 display reduced ability to differentiate to adipocytes compared to control cells. miR-17-92 cluster accelerates adipogenesis by negatively regulating retinoblastoma-like protein 2 (Rbl2) transcripts (187) . Adiponectin receptor 1 (ADIPOR1) is direct target of miR-221/222. miR-221 and miR-222 are inversely related to adiponectin levels and inhibit angiogenesis, thereby increasing hypoxia. Expression pattern of miR-27a/b in obesity is controlled by hypoxia. Number of macrophages infiltrating fat depot is associated with expression of miR-26b and miR-155 in subcutaneous and omental adipose tissue (100). miR-17-5p, miR-20a, and miR-106a are reported to suppress monocytic differentiation (188) . miR-223 plays crucial role in modulating macrophage polarization, suppressing infiltration of proinflammatory M1 macrophages by targeting PBX/knotted 1 homeobox 1 (Pknox1) in vitro (189). Concerning cytokine secretion, miR-132 activates NF-kB pathway and stimulates chemokine production, including IL-8 and chemokine C-C motif ligand 2 (CCL-2). miR-126 and miR196b reduce production of CCL-2. miR-155 down-modulates IL-1 production. miR-95 expression is negatively correlated with levels of CRP and IL-6. expression of miR-26b, miR-103, miR-143, miR-146b, miR-221, and miR-222 is regulated by TNF-a (100). miR-17, miR-29, miR-103, miR-107, miR-125a-3p, miR-132, and miR-320 are involved in obesity-related insulin resistance (190, 191) . Mechanisms by which miRNAs regulate gene expression in obesity have been reviewed elsewhere (20, 51, 192, 193) . Arrows indicate activation; blunted arrows, inhibition.
pressure, and coagulation, as well as inflammatory and immune responses (9, 18) . The complex network of cytokines balances proinflammatory and anti-inflammatory effects. Disequilibrium between pro-and anti-inflammatory cytokines or the uncontrolled production of cytokines can result in inflammatory phenomena (61) (62) (63) .
The expression of cytokines and proinflammatory factors, including IL-1, IL-4, IL-6, IL-8, IL-10, granulocytemacrophage colony-stimulating factor, VEGF, prostaglandin E2, cyclooxygenase 2 (COX-2), matrix metalloproteinases, and basic fibroblast growth factor, is highly regulated at many levels, including gene transcription, mRNA translation, and mRNA degradation (64) . Although so far virtually overlooked, the regulatory relationship between cytokines and miRNA seems to be reciprocal: not only do miRNAs target cytokine mRNA and thereby regulate cytokine expression, but also the cytokine signaling likewise has an impact on miRNA expression (65) . For instance, IL-1b and TNF-a are potent stimulators for miR-146a and miR-155 induction in a variety of cell types (21) . Importantly, miR-23b is down-regulated by IL-17, a cytokine that plays a profound role in the regulation of the innate immune activation (66) . The role of the miRNAs as regulators of the main proinflammatory mediators is reported next.
TNF-a
TNF-a is a proinflammatory cytokine predominantly synthesized by macrophages (67) . The regulation of production and secretion of this protein is multileveled and involves an extensive cross-talk at the intra-and extracellular level, including a self-regulatory loop (68) . TNF-a is synthesized as a 26 kDa transmembrane protein, which is cleaved by ADAM (A disintegrin and metalloproteinase) metallopeptidase domain 17 (ADAM17), a member of the metalloproteinase family (69) . This cleavage results in the release of the secreted 17 kDa form of TNF-a (70). Interestingly, several miRNAs have been shown to control TNF-a production, but at the same time, TNF-a affects the expression of several miRNAs, although some of these processes are still unclear. In this context, it has been hypothesized that miR-155 could directly increase TNF-a levels by augmenting transcript stability through binding to its 39 UTR region (71) . Alternatively, miR-155 could target gene transcripts coding for proteins that are known to act as repressors of TNF-a translation. Tili et al. (72) demonstrated that the up-regulation of miR-155 in LPS-activated macrophages resulted in an enhanced translation of TNFa mRNA. Additionally, mice overexpressing miR-155 produce more TNF-a when challenged with LPS (73). Moreover, in vivo studies showed that transgenic mice overexpressing miR-155 in the B cell lineage produce more TNF-a when challenged with LPS and are hypersensitive to LPS/D-galactosamine-induced septic shock with respect to their normal counterparts (72) . Some results also demonstrated that miR-155 and miR-146a serve as a mediator of the glucose-induced TNF-a/TGF-b1/NF-kB pathway (21) . Finally, one study showed that human monocyte exposure to cold (32°C) potentiated LPS-induced production of TNF and IL-6 while blunting IL-10 production (74). This dysregulation was associated with increased expression of miR-155, which potentiates TLR signaling by negatively regulating SH2 domain-containing inositol-5-phosphatase 1 (SHIP1) and suppressor of cytokine signaling 1 (SOCS1). Indeed, SHIP1 and SOCS1 were suppressed at 32°C, and miR-155 antagomirs increased SHIP1 and SOCS1 and reversed the alterations in cytokine production in coldexposed monocytes. In contrast, miR-155 mimics phenocopied the effects of cold exposure, reducing SHIP1 and SOCS1 and altering TNF and IL-10 production. Importantly, miR-155 deficiency reduced hypothermia and improved survival (78% vs. 32%), which was associated with increased SHIP1, SOCS1, and IL-10.
TNF-a is a strong inducer of NF-kB signaling. Thus, Lorente-Cebrian et al. (75) demonstrated that miR-145 overexpression regulated adipocyte lipolysis via multiple mechanisms involving increased production and processing of TNF-a in human adipocytes. The increase in TNF-a production by miR-145 was mediated via activation of p65, a member of the NF-kB complex. In addition, miR-145 also down-regulates the expression of the protease ADAM17, resulting in an increased fraction of membrane bound TNF-a, which is the more biologically active form of TNF-a (75). Moreover, it was recently shown in human nonadipose cells that miR-145 decreases ADAM17 expression by direct binding to the 39 UTR of the gene (76) . On the other hand, the treatment of preadipocytes with TNF-a for 24 h decreased miR-221 expression at all the concentrations tested (77) . miR-221 also is down-regulated by TNF-a in cultured human preadipocytes. In a study with human adipocytes, the treatment with TNF-a up-regulated miR-378 expression on the d 15 after the induction of preadipocyte differentiation (78) . The overexpression of miR-181a repressed TNF-a protein expression, while the inhibition had the opposite effect (79) . Additionally, miR181a suppression decreased the expression of fatty acid synthesis-associated genes (phosphodiesterase 3B and lipoprotein lipase, among others), revealing a new therapeutic target for antiobesity drugs.
The transfection of miR-346 in an LPS-activated human monocytic cell line (THP-1) has been shown to inhibit TNF-a secretion. miR-346 controls the release of TNF-a protein and the stability of its mRNA by regulating the stabilization of tristetraprolin, a RNA binding protein (80) . Moreover, it has been found that miR-146b-5p decreases the expression of TNF-a in THP-1 monocytes by a targeted repression of IL-1 receptor-associated kinase (IRAK) and TNF receptor-associated factor 6, two key adapter molecules in the IRAK/NF-kB pathway (30, 81) . Other miRNAs, such as miR-19a and miR-181, also regulate adipogenesis by affecting the expression of TNF-a as well as some genes involved in adipogenesis (82) . Furthermore, Schroen et al. (49) summarized the inverse regulation of miRNAs during adipogenesis and adiposity by TNF-a, including the upregulation of miR-221 and miR-222 and the inhibition of miR-103 and miR-104. By contrast, miR-125 may be implicated in the posttranscriptional repression of TNF-a mRNA-and hence the need for its down-regulation concerning TNF-a production (83) .
Of interest, TNF-a induces the down-regulation of miR-103 and miR-143 (54) and the up-regulation of miR-221 and miR-222 in adipocytes (54, 84) . Suarez et al. (85) reported that TNF-a increases the expression of miR-155, miR-31, miR-17, and miR-191 without changing miR-20a, miR-222, and miR-126 in human endothelial cells. Such investigation also evidenced that E-selectin and ICAM-1 are targets of TNF-a-induced miR-31 and miR-17-3p, respectively, regulating neutrophil binding to endothelial cells (85) . A constitutively expressed, endothelial cellrestricted miRNA (miR-126) modulated TNF-a-induced VCAM-1 expression (86) . Taken together, the recent results show that inducible miRNAs may make up a feedback loop to control TNF-a production in an inflammation context.
IL-1
IL-1 is a cytokine that plays a key role in inflammatory, immunity, infectious, and degenerative diseases (87, 88) . Although 2 different genes encode for IL-1a and IL-1b, both molecules bind to the same IL-1 receptor (IL-1R). However, they have diverse functions: whereas IL-1a is constitutively expressed in epithelial membranes of gastrointestinal tract, lung, liver, kidney, endothelial cells, and astrocytes, IL-1b is produced by monocytes and macrophages and in response to other cytokines (89, 90) . Thus, their expression levels are under strict control to ensure activity under the appropriate conditions.
As occurs with other cytokines, the expression of IL-1a and IL-1b is regulated by miRNAs. For example, in human gingival fibroblasts, IL-1b levels increased after miR-146 inhibition (91) . In cortical neuronal cells overexpressing miR-34a, miR-451, and miR-874 and subjected to stretch injury, mRNA levels of IL-1b and TNF-a were dramatically up-regulated (92) . Furthermore, miR-181 inhibition resulted in the up-regulation of inflammatory cytokines, including IL-1b (93) . IL-1 is produced by active leukocytes; it binds to its receptor and forms the TLR/IL-1 complex. Myeloid differentiation primary response protein 88 (MyD88) is the first adapter molecule recruited to the complex and activates the signaling pathway (94) . In this context, it has been described that miR-155 regulates MyD88 protein expression by translational repression (95) and leads to the suppression of IL-1 function.
On the other hand, IL-1b is predicted as a target of miR-21 and miR-132. Recent studies have shown that miR-21 is implicated in several processes in human and mouse tissues, including an anti-inflammatory effect in different inflammation-related diseases. Thus, LPS induces miR-21 expression, and miR-21 limits the LPS-induced inflammatory response (96) . Moreover, IL-1b is implicated in changing wound-associated macrophages to an antiinflammatory mode and also induces the expression of the anti-inflammatory cytokine IL-10 (96). In addition, miR-21 protects against inflammatory and injury responses in fatal colitis (97) . miR-132 may act as a homeostatic process counteracting inflammation both in experimental autoimmune encephalomyelitis and in inflammatory bowel disease (98, 99) . Furthermore, miR-132 is correlated with adipose tissue morphology, metabolic markers, leptin, and adiponectin (100).
IL-6
IL-6 is a proinflammatory cytokine that regulates energy homeostasis, cell proliferation, and inflammatory responses (101) . Increased IL-6 production is a hallmark of many human chronic inflammatory states, including sepsis, rheumatoid arthritis, and inflammatory bowel disease (102) . The diverse roles of IL-6 during the inflammatory response might be explained by the ability to initiate 2 modes of signaling: classic signaling via the interaction of IL-6 with its membrane-bound IL-6Ra subunit (103) , and trans signaling via a naturally occurring soluble IL-6Ra receptor that is proteolytically cleaved from the cell surface (104) . In both scenarios, IL-6 exerts specific actions via the signal transducers, leading to the activation of the Janus family kinases/STAT and MAPK cascades (103) . IL-6 expression is also regulated by NF-kB and is influenced by a variety of external stimuli. Various elements in the 39 UTR of IL-6 mRNA contribute to IL-6 mRNA degradation and regulate IL-6 expression (105, 106) .
The IL-6/STAT3 signaling pathway exerts complex actions in regulating the innate immune response (107) . Activation of STAT3 may promote IL-6 production, and IL-6 itself can lead to the phosphorylation of STAT3 (108). Chen et al. (107) demonstrated that the expression of IL-6 in response to LPS initiates a positive feedback loop in which secreted IL-6 down-regulated miR-223 expression, leading secondarily to an increase in STAT3, which then drove the expression of IL-6 and IL-1b in a positive regulatory loop. The change in miR-223 expression was also accompanied by a substantial increase in STAT3 protein expression. Furthermore, the overexpression of miR-223 was associated with a significant decrease in STAT3 levels and a reduction in the production of IL-6 and IL-1b, while miR-223 antagomirs (antisense oligonucleotides) increased the production of IL-6 and IL-1b. Interestingly, IL-6 was found to be a main factor in inducing the decrease in miR-223 expression after LPS stimulation, which formed a positive feedback loop to regulate IL-6 and IL-1b (107) .
On the other hand, miR-146a/b up-regulation provides a negative feedback on the innate immune system, being another important regulator of IL-6 metabolism (109). Bhaumik et al. (110) showed in human fibroblasts that the overexpression of miR-146a/b suppressed IL-6 and IL-8 secretion and down-regulated IRAK, a crucial component of the IL-1 receptor signal transduction pathway. The authors hypothesized that the increased expression of miR146a/b served to restrain the excessive secretion of the inflammatory cytokines IL-6 and IL-8, thereby limiting inflammation in this context. It has been reported that miR146a mimics decreased, while miR-146a inhibitor increased, the expression of IL-6 but did not affect TNF-a expression in LPS-stimulated RAW264.7 cells (109). The authors proposed that miR-146a might function as a negative feedback in the Notch1 signaling pathway during the LPS-induced production of inflammatory cytokines. Notch signaling is a highly conserved pathway that plays an important role in inflammatory disorders (111) . It can act cooperatively with TLR pathways to activate Notch target genes and increase the production of TLR-induced cytokines in macrophages. Such study confirmed that miR146a may play a critical role in the inflammatory response.
An assay with monocyte-derived cells demonstrated that IL-6-mediated suppression of miR-200c directs the constitutive activation of an inflammatory signaling circuit (112) . The autoregulatory loop is established and maintained by the IL-6-directed suppression of miR-200c expression.
Furthermore, signals downstream of this regulatory RNA bifurcate to regulate p65 activity vs. that of a Jun NH2-terminal kinase to heat shock factor 1 pathway, which are required to demethylate the IL-6 promoter to facilitate p65/c-Jun-directed transcription of IL-6 (112). Dou et al. (113) , in a study with hepatocytes of db/db mice (C57BL/ KsJ), found that the expression of miR-200s was decreased and was accompanied by elevated levels of IL-6. Moreover, the treatment with IL-6 (10 ng/ml for 24 h) suppressed the expression of miR-200s. The authors proposed than IL-6 impairs activation of the PI3K/protein kinase B (AKT)/ glycogen synthase kinase pathway via down-regulation of miR-200s, and up-regulation of the transcriptional regulator friend of Gata 2, a multitype zinc finger protein that influences gene transcription by specifically interacting with other transcription factors (114) .
Further, it has been demonstrated that miR142-3p directly targets the 39 UTR of IL-6 in dendritic cells (115) and that IL-6 expression decreases in hematopoietic cells in a miR142-3p-dependent manner (116) . An IL-6/miR142-3p feedback loop-dependent regulation process has been described. Thus, IL-6 inhibits miR142-3p expression by inducing DNA methyltransferase 1-mediated hypermethylation of the miR142-3p promoter (117) . Interestingly, miR142-3p also suppresses IL-6 secretion by targeting the 39 UTR of IL-6. Also, the overexpression of let-7 via the transfection of let-7 precursors decreases IL-6 expression, which is consistent with the inhibition of IL-6 39 UTR luciferase activity in bone marrow-derived mesenchymal stem cells (118) . However, even if IL-6 contains a potential binding site for let-7a in its 39 UTR, another study reported different data. Overexpression of let-7a in vitro increased IL-6 production in stimulated mesangial cells compared to nontransfected controls (119) . These data open the door to studies examining the role of let-family expression in inflammation.
Of interest, miR-329 plays a pivotal role in the inhibition of IL-6 mRNA expression by targeting the NF-kB subunit, p65 (120) . Moreover, the same study showed than miR-23a and let-7c directly regulate the inhibition of IL-6 mRNA. In the same way, miR-132 expression is inversely related with IL-6 levels in patients with nonalcoholic fatty liver disease (100). Together, these findings suggest that multiple miRNAs are involved in the regulation of IL-6 expression.
IL-18
IL-18 is a cytokine of the IL-1 family that is expressed as an inactive form and subsequently activated by proteolytic cleavage performed by caspase 1, which belongs to the NODlike receptor (NLR) complex (121) . IL-18 is produced in a variety of tissues and has been associated with inflammatory function, autoimmune diseases, and cancer (122, 123) . For example, IL-18 has a predictive role in the development of type 1 diabetes (124), whereas its serum levels are correlated with hyperglycemia and atherogenesis in patients with type 1 diabetes (125) . Only miR-197 has been studied in relation to IL-18. This miRNA interacts with the mRNA sequence of IL-18 and inhibits the expression of the cytokine (126) . Moreover, the expression of miR-197 is inversely correlated with the levels of IL-18 in peripheral blood mononuclear cells from patients with hepatitis B (126).
ICAM-1
ICAMs are glycoproteins belonging to the immunoglobulin superfamily that bind to b2 integrins present in leukocytes (127) . ICAM-1 is considered the most important adhesion molecule for leukocyte recruitment to inflamed areas (128) . Recent studies have demonstrated that ICAM-1 expression is under critical control of a number of miRNA species, such as miR-221, miR-222, and miR-339. These miRNAs are complementary to ICAM-1 39 UTR region and modulate ICAM-1 expression at the postranscriptional level by binding to the untranslated region. Thus, miR-221 and miR-222 down-regulate ICAM-1 expression in HUVEC and lead to significant reduction of monocyte adhesion to the cells (129) . miR-221 is downregulated in the human subcutaneous adipose tissue of obese patients compared to nonobese individuals (130) and can be related to chronic inflammatory state in obesity. In addition, miR-221 and miR-222 are down-regulated during adipogenesis and associated with BMI in human adipose samples (130) . Different studies have examined the modulation of ICAM-1 molecule by miRNAs in diseases with inflammatory responses. Indeed, in an important group of biliary disorders called cholangiopathies, IFN-g suppresses miR-221, resulting in increases of ICAM-1 expression in cholangiocyte cells and further regulation of inflammatory responses in cholangiopathies (131) . In glioblastoma multiforme cells, the suppression of ICAM-1 by miR-222 and miR-339 is related to tumor escape from the host immune response and therefore to poor prognosis (132) . Finally, Kim et al. (133) have reported that ICAM-1 is up-regulated by miR-130 during the inflammatory response.
VCAM-1
VCAM-1 is a sialoglycoprotein that belongs to the immunoglobulin superfamily (134) . In response to metabolic and inflammatory activation, this intercellular adhesion molecule is up-regulated in endothelial cells (135) and mediates leukocyte adhesion by interacting with its integrin ligand, which is expressed in the membrane of leukocytes and activated neutrophils (136) . An increase in VCAM-1 expression in endothelial cells is associated with the promotion of inflammation and tissue damage (134) . miR-126 (also referred as miR-126-3p), along with its analogous strand (antisense) miR-126* (referring to the 59 part of the transcript, also called miR-126-5p), is the most studied miRNA in relation with the regulation of VCAM-1.
In mammals, miR-126 is expressed from intron 7 of epidermal growth factor-like domain 7, an endothelial cell-derived secreted protein essential for proper vascular development (137) . This miRNA can bind to the 39 UTR of the transcript for human VCAM-1 (86), inhibiting mRNA translation and suppressing de novo protein synthesis (138) , thereby blocking adhesion and infiltration of leukocytes into the vasculature wall. Transfection of endothelial cells with an antisense construct to target endogenous miR-126 permits an increase in TNF-a-stimulated VCAM-1 expression (86) . Classically, miR-126 participates in biologic processes like angiogenesis and primitive erythropoiesis (139) , and it has a potential role in the development of renal microvascular inflammation and dermatomyositis (83, 140) . However, a major emerging function of miR-126 is to regulate key molecules in PI3K/AKT and MAPK signaling pathways. It does change the expression levels of both negative regulators like sprouty-related EVH1 domain-containing protein 1 and phosphoinositide kinase 3 regulatory subunit 2 (PIK3R2 or p85b), and activators like insulin receptor substrate 1 (141) . Agudo et al. (142) demonstrated that miR-126 is specifically expressed in plasmacytoid dendritic cells and controls the function of these cells. It regulates the expression of genes encoding molecules involved in the innate response, such as VEGF receptor 2, suggesting new opportunities for therapeutic purposes. In this sense, miR-126 up-regulation could promote chronic inflammation and autoimmunity, and a balanced expression of miR-126 should be sought to avoid the development of several pathologies. As a consequence, miR-126 could be considered a new modulator of innate immunity [for review, see (143)].
PAI-1
PAI-1 has been described as a member of the serine protease inhibitor superfamily (144) that inhibits the activation of both plasminogen activator and urokinase-type plasminogen activator, which act in fibrinolysis (145) . PAI-1 is produced by fibroblasts, endothelial cells, and platelets (146, 147) , and its expression increases with hypoxia and reactive oxygen species (148) . This peptide has a variety of biologic functions and is involved in different diseases, such as systemic inflammation, atherosclerosis, metabolic syndrome, fibrosis, and cancer, as has been reviewed by Iwaki et al. (149) . Inflammatory response regulators, such as monocytes, TNF-a, IL-1b, and LPS, are known to stimulate PAI-1 production in endothelial cells (150) . Recent studies have described some miRNAs that bind to the 39 UTR of PAI-1 and inhibit its production. For example, under hypoxic conditions, PAI-1 expression is augmented in fibroblasts by decreasing miR-449a/b expression (148) . Other miRNAs that bind to the 39 UTR of PAI-1 and downregulate its expression are miR-30c, miR-421, miR-486, and miR-449a/b. Both miR-30c and miR-421 inhibit PAI-1 expression in endothelial cells, lowering PAI-1 plasma levels (151) . Moreover, miR-30c induces human adipocyte differentiation while repressing PAI-1 expression in adipose tissue (152) . It has been also shown that miR-486 is repressed and leads to the up-regulation of PAI-1 in liposarcoma or adipose tissue-derived tumors (153) . The stress conditions also modify PAI-1 levels through miRNAs regulation.
OTHER NONCODING RNAS AND REGULATION OF INFLAMMATION lncRNAs
Although only a handful of lncRNAs have been fully characterized-the result of the emergence of microarray and high-throughput sequencing techniques-the interest in these regulatory molecules is increasingly growing. They are noncoding RNAs longer than 200 nt with important roles in diverse biologic functions, including inflammation (154) . Cui et al. (155) identified a number of lncRNAs with altered expression in response to LPS stimulation. One of the most up-regulated transcripts was lnc-IL7R, which overlaps with the 39 UTR of the human IL-7 receptor a-subunit gene (IL7R). When transfected, it was able to diminish the LPS-induced inflammatory response. Another lncRNA, Ptprj-as1, is highly expressed in macrophage-enriched tissues and is transiently induced by proinflammatory factors, such as LPS (156) . Rapicavoli et al. (157) studied the lncRNAs induced by inflammatory signaling via TNF-a. Among the hundreds of lncRNAs whose expression was modified, including 54 pseudogene lncRNAs, Lethe (a pseudogene lncRNA) was selectively induced when TNF-a activated NF-kB, and it functioned in negative feedback signaling to NF-kB by binding to this transcription factor and preventing it from interacting with DNA (157) . Also, microbial recognition receptors, such as the TLRs, are able to induce the expression of numerous lncRNAs. One of them is lncRNA-COX-2, which mediates both the activation and repression of distinct classes of immune genes (158) . Another lncRNA, nuclear enriched abundant transcript 1, induces the expression of antiviral genes, including IL-8 (159) . Finally, in osteoarthritis, lncRNA H19, known for influencing IGF-2 expression, was found to be significantly up-regulated. However, proinflammatory cytokines, such as IL-1b and TNF-a, downregulated the expression of lncRNA H19 as well as that of miR-675 (160) . With this background, more research is needed to identify lncRNAs implicated in the regulation of the inflammatory processes.
Long intergenic noncoding RNAs
The long intergenic noncoding RNAs (lincRNAs) are a newly described subtype of noncoding RNAs that can act as regulators for both transcription and posttranscriptional/ translation (161) . Some of them were recently identified in blood and adipose tissue during lowdose experimental endotoxemia with LPS in humans, and 2 of them, linc-TP53I13 and linc-DMRT2, were suppressed in adipose tissue of obese humans (162) . Other lincRNA, such as lincRNA-DYNLRB2-2, inhibited inflammation through G protein-coupled receptor 119 in THP-1 macrophage-derived foam cells by promoting ABCA1-mediated cholesterol efflux (163) . Finally, a total of 159 lincRNAs were found to be differentially expressed following innate activation of THP1 macrophages (164) . Among them, linc1992, called TNF and HNRNPL-related immunoregulatory lincRNA (THRIL), was required for the expression of many cytokines and immune response genes, particularly TNF-a, by binding to its promoter.
Circular RNAs
There are thousands of endogenous circular RNA (circRNAs) in mammalian cells, some of which are highly abundant and evolutionarily conserved. Evidence is emerging that some circRNAs might regulate miRNA function, and roles in transcriptional control have also been suggested. A recent review has described methods for the identification and characterization of endogenous circRNAs, including molecular methods and genomewide approaches, with a focus on the advantages and disadvantages of various techniques (165) . Therefore, the study of this class of noncoding RNAs has potential implications for therapeutic and research applications in inflammation-related diseases. To understand the regulation and function of these unusual molecules is a future challenge within this field.
NONCODING RNA CHANGES IN RESPONSE TO ANTI-INFLAMMATORY DRUGS
Although it is not the main topic of this review, it has been described that several drugs can exert their beneficial effects at least in part through the regulation of the expression of some miRNAs. Despite their secondary effects, steroidal and nonsteroidal anti-inflammatory drugs are being used in the control and management of several inflammation-related diseases, including autoimmune diseases (166) . Several studies, both in silico (167) and in animals (168) , have reported that these drugs can affect the expression of many miRNAs involved in the inflammatory response. For example, celecoxib, a nonsteroidal antiinflammatory drug, up-regulated miR-222 while deterring aromatase-expressing breast tumor growth in mice (168) . Budenoside, a steroid that reduces inflammation, has been reported to protect the lung from cigarette smoke-induced miRNA alterations and changed the smoking-related dysregulation of miRNA expression in liver (169) . Resolvins are compounds that are made by the human body from the v-3 fatty acids (170) . It has been described that resolvin D1 anti-inflammatory actions are mediated by the upregulation of specific miRNAs, such as miR-208a and miR-219, and their target anti-inflammatory genes, including IL-10 (171). In summary, although the development of antiinflammatory drugs targeting miRNAs and modulating their expression represents a promising therapeutic approach, there is much work to be done in the coming years.
CONCLUSIONS AND FUTURE DIRECTIONS
The role of noncoding RNA in the coordination of diverse cellular functions, such as stem cell maintenance, differentiation, and apoptosis, underscores their emerging importance as regulators of cellular homeostasis, especially of the inflammatory process, as reviewed here. Gene expression is a complex, dynamic process influenced by the environment (i.e., diet, stress, and toxins) in which the noncoding RNAs are involved in the regulation of pathways associated with the development of inflammationrelated diseases. In this way, the noncoding RNAs are related to predisposition and development of inflammationrelated diseases, including obesity, atherosclerosis, type 2 diabetes, osteoarthritis, autoimmune diseases (e.g., lupus erythematosus, multiple sclerosis, type 1 diabetes, inflammatory bowel disease, celiac disease), asthma, periodontitis, and cirrhosis.
There are 2 promising applications of noncoding RNAs in the prognosis and treatment of these diseases. First, noncoding RNAs can be used as susceptibility biomarkers, early prognostic biomarkers, confirmatory biomarkers of disease, or biomarkers of treatment response (58, 172) . The levels of cell-free miRNAs in serum are stable and reproducible, and they are emerging as new noninvasive biomarkers for the diagnosis of different types of cancer (173) and other diseases, including inflammation-related diseases (174) . These circulating miRNAs are protected by microvesicles and protein/lipoprotein complexes (highdensity lipoprotein, low-density lipoprotein complexes) in order to avoid RNase-mediated degradation, and they might contribute to intercellular signaling (172) .
Second, noncoding RNAs could be used as a therapeutic strategy in inflammation-related diseases. In this case, 2 approaches are being investigated: the down-regulation or antagonization of the miRNAs related with the disease, and the administration of exogenous miRNAs that mimic the action of the endogenous beneficial ones (175) . A growing body of evidence suggests that antagonizing miRNA activity through the use of miRNA inhibitors or synthetic antimiRNA oligonucleotides, perfectly antisense to naturally occurring miRNAs, may be a useful approach to quench the pathogenic effects of up-regulated miRNAs (176) . These specifically designed anti-miRNAs may have their half-life extended through the use of various strategies, including locked nucleic acid probes (177). Some studies have been shown to be highly efficacious in human cells in primary culture, but the implementation of these technologies in human clinical trials awaits further development (178) . On the other hand, the administration of miRNA inducers that increase the expression of tissuespecific miRNAs could be an alternative approach for the management of inflammation-related diseases (30) . Similarly, the administration of systemic miRNAs (miRNA mimics) or introducing genes coding for miRNAs into viral constructs or liposomes could be used as a future targeted therapy for many diseases (179) . In this way, the development of nanotechnologies for increasing the bioavailability and the delivery of the exogenous miRNAs in order to specifically target the desired cells or tissues (i.e., small nanoparticles that effectively complex miRNA and facilitate the uptake of miRNA into the cells) is rapidly progressing (180) . Although the immune responses related to the carriers remain to be addressed, liposome-, metal-and polymer-mediated miRNA delivery (181), or even intravenous delivery of virus-mediated miRNAs (182) , have been achieved in the treatment of cancer and liver disease.
The development of miRNA-based therapies for inflammation-related diseases is warranted because of the severe problem that these diseases represent to society. However, huge challenges remain to be overcome before the clinical use of miRNA-targeting therapeutics, especially in relation to the development of safe and effective delivery of targeting miRNAs in specific tissues in vivo (183) . Among these remaining questions, we can highlight that one individual miRNA has multiple potential targets, which may coordinate or antagonize each other's functions. In addition, the interactions between miRNAs and mRNAs depend on the cell type and tissue, which explains the difficulties in predicting the side effects that may be associated with miRNA-based therapies. In order to affect only the intended organ, a solution is the conjugation of the anti-miR oligonucleotides with ligands for target organ specific cell surface receptors (184) . In spite of these difficulties, the next few years will see the development of miRNA-based therapies that, after being tested for safety and efficacy in animal models, could be used in the treatment of metabolic, autoimmune, and degenerative diseases, cancer, and many other conditions that are characterized or associated with chronic inflammation.
